近日，贝康医疗（02170.HK）旗下Gems一步式胚胎培养液正式斩获中国医疗器械注册证（国械注进 20253180071），这一里程碑事件不仅标志着公司完成IVF全链条布局的关键闭环，更精准切入百亿级 辅助生殖耗材蓝海市场，抢占国产替代核心赛道，为公司带来确定性业绩增量，成为驱动股价估值双重 提升的核心催化剂，给广大股民及投资机构释放明确的长期投资信号。 一、构筑核心竞争壁垒，奠定盈利基础 此次获批的Gems一步式胚胎培养液，并非普通国产产品，而是贝康医疗通过收购澳大利亚Genea Biomedx（BMX）纳入麾下的国际顶尖资产——其技术源自全球辅助生殖标杆机构悉尼IVF中心，由"培 养液之父"David Mortimer教授毕生研发，经过12年临床验证、诞生数万名健康婴儿，获得美国FDA、 欧洲CE、澳洲TGA等多地区标准认证，代表当前胚胎培养液领域的最高技术水平，具备极强的临床竞 争力与市场稀缺性。 值得投资人重点关注的是，贝康医疗通过此次收购，不仅获得了Gems这一核心产品，更掌控了全球领 先的胚胎培养技术体系——要知道，新加坡BMX作为全球顶尖胚胎培养液及培养箱技术引领者，其产 品此前授权Cook品 ...

Core Insights - The article highlights the significant progress made by Beikang Medical in the assisted reproduction sector, particularly in the context of supportive fertility policies and the company's focus on high-value business and product optimization [1][3]. Financial Performance - In the first half of 2025, Beikang Medical reported revenue of 1.01 billion yuan, a year-on-year decrease of 19%, attributed to industry slowdown and a strategic reduction in low-margin businesses [3]. - Despite the revenue decline, overseas income grew by 9%, and EBITDA losses decreased by 5%, indicating improved core operational metrics with a 16% increase [3]. - The gross profit margin rose by 6.1 percentage points to 52.5%, with high-margin products increasing their share [3]. - The company achieved a 19% improvement in operating cash flow, with cash and cash equivalents totaling 544 million yuan as of June 30, 2025, reflecting a robust financial structure [3]. PGT Business Growth - The PGT (Preimplantation Genetic Testing) business emerged as a core growth driver, generating revenue of 55.85 million yuan, a 9% increase year-on-year, despite an overall decline in the IVD testing industry [6]. - The company maintained a high bid-winning rate of 83% in PGT business tenders, reinforcing its market share and competitive advantage [6]. Localization of Culturing Solutions - Beikang Medical achieved a significant milestone in localization with the registration of the Geri time-lapse incubator and the VitBase culture medium, marking the first true domestic alternatives to previously imported products [8]. - The embryology laboratory business benefited from this localization trend, with revenue reaching 42.446 million yuan, a 35% increase, driven by the sales of high-value consumables [8]. AI and Full Industry Chain Integration - The company has established a unique position in the industry by achieving an "AI + full industry chain closed loop," covering sperm analysis, embryo culture, and cryopreservation, which is a first in China's assisted reproduction field [12]. - This integration is expected to enhance clinical pregnancy rates and laboratory efficiency, laying a solid foundation for future industry upgrades and long-term growth [14].